medigraphic.com
Colegio de Medicina Interna de México.

2017, Number 5

<< Back Next >>

Med Int Mex 2017; 33 (5)

Yellow fever: A concise review given the current epidemiological scenario

Valente-Acosta B, García-Acosta J

Language: Spanish
References: 34
Page: 648-654
PDF size: 398.38 Kb.


ABSTRACT

Mosquitoes transmit yellow fever, a viral infection characterised by haemorrhage and jaundice. Currently, it is endemic in African and South American countries whereas our country has been declared free of the disease since 1959 following the latest outbreaks and epidemics occurred in coastal cities from both the Gulf of Mexico and the Pacific coast that were registered from the Colony until the middle of century XX. In 1881, Carlos J Finlay, who was a Cuban physician, exposed the hypothesis concerning the transmission of yellow fever by vectors; such theory was corroborated in 1890. In 1903, Mexico started working to eradicate the disease through control of mosquitoes. Finally, in 1923 Mexico achieved the control of the disease with the last urban case registered, whereas the last jungle case was recorded in 1959. However, due to the resurgence of the disease in our continent, it is important to provide the clinician with a comprehensive review of the disease and to raise awareness of the possible occurrence of imported or autochthonous cases in our territory.


REFERENCES

  1. Secretaría de Salubridad y Asistencia, Control de enfermedades transmisibles, Publicación Científica No. 1 México: SSA, 1972;79-84.

  2. García de Alba GJ, Salcedo RAL. Fiebre amarilla en Mazatlán 1883. Espiral Estudios sobre Estado y Sociedad 2006;12(35):121-147.

  3. Finlay CJ. El mosquito hipotéticamente considerado como agente de transmisión de la fiebre amarilla. En: Buck C, Llopis A, Nájera E, Terris M. El desafío de la epidemiología. Problemas y lecturas seleccionadas. Publicación Científica No. 505. Washington, DC, USA: Organización Panamericana de la Salud, 1988;63-68.

  4. Novo, S. Breve Historia y Antología sobre la Fiebre Amarilla. Salud Púb Méx 1995;37(1):99-102.

  5. García de Alba GJ, Salcedo RAL. Fiebre amarilla en México, hace 120 años. Cir Cir 2002;70:116-123.

  6. Staples JE, Monath TP. Yellow fever: 100 years of discovery. JAMA 2008;300(8):960-2.

  7. Rice CM, Lenches EM, Eddy SR, et al. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 1985;229(4715):726-33.

  8. Kuhn S, Twele-Montecinos L, MacDonald J, et al. Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. Can Med Assoc J 2011;183:E243-5.

  9. Rosen L. Transovarial transmission of arboviruses by mosquitoes. Med Trop (Mars) 1981;41(1):23-9.

  10. Monath TP. Facing up to re-emergence of urban yellow fever. Lancet 1999;353(9164):1541.

  11. Goenaga S, Fabbri C, Dueñas JC, Gardenal CN, Rossi GC, et al. Isolation of yellow fever virus from mosquitoes in Misiones province, Argentina. Vector Borne Zoonotic Dis 2012;12:986-93.

  12. Vasconcelos PFC. Yellow fever. Rev Soc Bras Med Trop 2003;36:275-293.

  13. Moreno ES, Spinola R, Tengan CH, et al. Yellow fever epizootics in non-human primates, São Paulo state, Brazil, 2008-2009. Rev Inst Med Trop Sao Paulo 2013;55:45-50.

  14. Barrett AD, Higgs S. Yellow fever: a disease that has yet to be conquered. Annu Rev Entomol 2007;52:209-29.

  15. Bres PL. A century of progress in combating yellow fever. Bull World Health Organ 1986;64(6):775-86.

  16. Garske T, Van Kerkhove MD, Yactayo S, et al. Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med 2014;11(5):e1001638.

  17. Monath TP. Yellow fever: an update. Lancet Infect Dis 2001;1(1):11-20.

  18. Monath TP, Woodall JP, Gubler DJ, et al. Yellow fever vaccine supply: a possible solution. Lancet 2016;387(10028):1599-600.

  19. Chan M. Yellow fever: the resurgence of a forgotten disease. Lancet. 2016 May 28;387(10034):2165-6.

  20. Vasconcelos PF, Costa ZG, Travassos da Rosa ES, Luna E, Rodrigues SG, Barros VL, Oliveira RC, Sousa MR, Barbosa da Silva J, Cruz AC, Martins EC, Travassos da Rosa JF. Epidemic of jungle yellow fever in Brazil, 2000: implications of climatic alterations in disease spread, J Med Virol 2001;65:598-604.

  21. http://www1.paho.org/hq/dmdocuments/2009/eid_updates_ 2009_03_31_yf.pdf Consultado 10 de abril 2017

  22. http://portalsaude.saude.gov.br/index.php/o-ministerio/ principal/leia-mais-oministerio/619-secretaria-svs/ l1-svs/27300-febre-amarela-informacao-e-orientacao - Consultado 10 de abril 2017

  23. Monath TP, Gershman M, Staples EJ, Barrett ADT. Capítulo 36: Yellow fever vaccine. En: Plotkin SA, Orenstein WA, Offit PA, editores. Vaccines. 6th ed. Saunders Elsevier; 2012;870-96.

  24. Tuboi SH, Costa ZG, da Costa Vasconcelos PF, Hatch D. Clinical and epidemiological characteristics of yellow fever in Brazil: analysis of reported cases 1998-2002. Trans R Soc Trop Med Hyg 2007 Feb;101(2):169-75.

  25. Allwinn R, Doerr HW, Emmerich P, Schmitz H, Preiser W. Cross-reactivity in flavivirus serology: new implications of an old finding? Med Microbiol Immunol 2002 Mar;190(4):199-202.

  26. Houghton-Triviño N, Montaña D, Castellanos J. Dengueyellow fever sera cross-reactivity; challenges for diagnosis. Rev Salud Publica (Bogota) 2008;10(2):299-307.

  27. Centers for Disease Control and Prevention (CDC). Biosafety in Microbiological and Biomedical Laboratories (BMBL) 5ª ed. 2009.

  28. Gardner C, Ryman K. Yellow fever: A reemerging threat. Clin Lab Med 2010;30(1):237-260.

  29. Monath TP, Cetron MS. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 2002;34:1369- 1378.

  30. Sbrana E, Xiao SY, Guzman H, et al. Efficacy of post-exposure treatment of yellow fever with ribavirin in a hamster model of the disease. Am J Trop Med Hyg 2004;71:306-12.

  31. World Health Organization. WHO Working Group on technical specifications for manufacture and evaluation of yellow fever vaccines, Geneva, Switzerland, 13-14 May 2009. Vaccine 2010;28:8236-45.

  32. Roukens AH, Vossen AC, Bredenbeek PJ, et al. Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial. PLoS ONE 2008;3(4):e1993.

  33. Khromava AY, Eidex RB, Weld LH, et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005;23:3256-63.

  34. Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine 2008;26:6077-82.




2020     |     www.medigraphic.com